Ekspresi HER2 dan Grading Histopatologis Nottingham pada Karsinoma Payudara: A Systematic Review
DOI:
https://doi.org/10.55606/jikki.v6i1.9058Keywords:
Breast Cancer, HER2, Histologic Grade, Immunohistochemistry, Invasive CarcinomaAbstract
Breast cancer is the most common malignancy among women worldwide. Histopathological grade and HER2 status are well-established prognostic factors in invasive breast carcinoma, yet findings regarding their association remain inconsistent. This systematic review aims to summarize current evidence on the relationship between HER2 expression and histologic grade in invasive breast cancer. Methods: The review followed PRISMA 2020 guidelines. Searches were conducted in PubMed, ScienceDirect, Google Scholar, DOAJ, and Garuda using keywords related to HER2, breast cancer, and histologic grade. Eligible studies were observational research reporting HER2 status assessed by immunohistochemistry, with or without FISH confirmation, and histologic grading based on the Nottingham/Elston–Ellis system. Data extraction and risk-of-bias assessment were performed using a standardized form and the Newcastle Ottawa Scale. Results: Eleven studies met the inclusion criteria, involving more than 255,000 patients from various populations. Four studies found a significant association between HER2 positivity and high histologic grade, especially those using combined IHC–FISH testing. In contrast, seven studies mostly using IHC alone reported no significant association. Substantial heterogeneity was identified in HER2 assessment techniques, patient characteristics, and grade distribution. Overall risk of bias was moderate. Conclusion: Evidence regarding the relationship between HER2 overexpression and high histologic grade remains inconsistent. Although some studies indicate a correlation, methodological differences and population variability contribute to conflicting results. HER2 status and histologic grade should therefore be viewed as complementary, not interchangeable, prognostic markers. Further well-designed prospective studies with standardized HER2 testing protocols are needed to clarify this association.
References
Abousahmeen, A. M., et al. (2023). Molecular subtypes and clinicopathological features of breast cancer. Annals of Translational Medicine, 11(8), 291. https://doi.org/10.21037/atm-22-6487
Aini, N., Dian, P., & Anggraini, D. (2015). Hubungan reseptor estrogen, reseptor progesteron dan ekspresi HER2/Neu dengan grading histopatologi pada pasien kanker payudara. Smart Medical Journal, 3(2), 97–100. https://doi.org/10.13057/smj.v3i2.35228
Aman, N. A., et al. (2019). HER2 overexpression in invasive breast cancer. Journal of Oncology, 4327651. https://doi.org/10.1155/2019/4327651
Bilous, M., Ades, C., Armes, J., Bishop, J., Brown, R., Cooke, B., et al. (2003). Predicting the HER2 status of breast cancer from basic histopathology: An analysis of 1500 breast cancers from the HER2000 International Study. The Breast, 12(2), 92–98. https://doi.org/10.1016/S0960-9776(02)00273-4
Bouchbika, Z., et al. (2012). Association between Her-2 overexpression and other prognostic factors. Open Journal of Pathology, 2(4), 97–102. https://doi.org/10.4236/ojpathology.2012.24018
Chibon, F., de Mascarel, I., Sierankowski, G., Brouste, V., Bonnefoi, H., MacGrogan, G., et al. (2009). Prediction of HER2 gene status in HER2 IHC 2+ invasive breast cancer: Comparison of ASCO/CAP and FDA guidelines. Modern Pathology, 22(3), 403–409. https://doi.org/10.1038/modpathol.2008.195
College of American Pathologists. (2023). HER2 testing in breast cancer: Guideline update. https://www.cap.org
Elston, C. W., & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. Histopathology, 19(5), 403–410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
Engstrøm, M. J., et al. (2013). Molecular subtypes and survival. Breast Cancer Research and Treatment, 140(3), 463–473. https://doi.org/10.1007/s10549-013-2601-3
Farshid, G., et al. (2020). Impact of 2018 ASCO–CAP guidelines on HER2 classification. Modern Pathology, 33(7), 1215–1223. https://doi.org/10.1038/s41379-020-0555-7
Galea, M. H., et al. (1992). Nottingham prognostic index. Breast Cancer Research and Treatment, 22(3), 207–219. https://doi.org/10.1007/BF01840832
Guo, X., Chen, L., Lang, R., & Fan, Y., et al. (2015). Evaluation of HER2 status in breast cancers with IHC 2+ using FISH. International Journal of Clinical and Experimental Pathology, 8(7), 8500–8506. http://www.ijcep.com
Harist, M., et al. (2024). Molecular subtypes in Indonesian breast cancer. Jurnal Kedokteran dan Kesehatan Indonesia. https://doi.org/10.20885/JKKI.Vol15.Iss1.art7
Ishaque, N. (2014). Her-2 overexpression and association with tumor grade. Annals of PIMS, 10(1), 15–20.
Ivanova, M., et al. (2024). Standardized pathology report for HER2 testing. Virchows Archiv. https://doi.org/10.1007/s00428-023-03656-w
Li, X., Dai, D., Chen, B., Tang, H., et al. (2015). Clinicopathological features and molecular categories of breast cancer. OncoTargets and Therapy, 8, 93–102. https://doi.org/10.2147/OTT.S73217
Liu, T., Lin, H., & Li, Q., et al. (2015). HER2 status in breast cancer: Comparison of IHC, FISH, and prognosis. Diagnostic Pathology, 10, 78. https://doi.org/10.1186/s13000-015-0282-5
Ménard, S., et al. (2001). HER2 overexpression in various tumors. Annals of Oncology, 12(Suppl 1), S15–S19. https://doi.org/10.1023/A:1012532118522
Miglietta, F., et al. (2009). HER2 in small breast carcinomas and correlation with grade and proliferation. Breast Cancer Research and Treatment, 117(2), 377–380. https://doi.org/10.1007/s10549-008-0282-z
Muhartono, M., Ramanisa, S., Mutiara, H., & Riduan, R. (2016). Hubungan antara ER, PR, dan HER2 dengan derajat keganasan karsinoma payudara. Majalah Kedokteran Andalas, 39(2), 65–72. https://doi.org/10.25077/mka.v39.i2.p65-72.2016
Nelson, H., Johnson, C., & O’Meara, E., et al. (2022). Histologic grade and breast cancer-specific mortality in a large U.S. cohort. The Breast, 66, 123–130. https://doi.org/10.1016/j.breast.2022.08.014
Orrantia-Borunda, E., et al. (2022). Subtypes of breast cancer. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK583808/
Parise, C. A., & Caggiano, V. (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade. Journal of Cancer Epidemiology, 2014, 469251. https://doi.org/10.1155/2014/469251
Park, S., et al. (2012). Outcomes by molecular subtype. The Breast, 21(1), 50–57. https://doi.org/10.1016/j.breast.2011.07.009
Payandeh, M., et al. (2016). Correlation of HER2 with prognostic variables. Asian Pacific Journal of Cancer Prevention, 17(3), 1343–1347. https://doi.org/10.7314/APJCP.2016.17.3.1343
Rakha, E. A., et al. (2008). Prognostic significance of Nottingham grade. Journal of Clinical Oncology, 26(19), 3153–3158. https://doi.org/10.1200/JCO.2007.15.5986
Thomas, E., et al. (2000). Prognostic implications of HER2. The Breast, 9(5), 269–271. https://doi.org/10.1054/brst.2000.0182
Warjianto, W., Soewoto, W., Alifianto, U., & Wujoso, H. (2020). Hubungan ER, PR, dan HER2/neu dengan grading histopatologi. Smart Medical Journal, 3(2), 97–100. https://doi.org/10.13057/smj.v3i2.35228
Wolff, A. C., et al. (2018). ASCO/CAP HER2 testing guideline update. Journal of Clinical Oncology, 36(20), 2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jurnal Ilmu Kedokteran dan Kesehatan Indonesia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
